Head-To-Head Survey: Dogwood Therapeutics (NASDAQ:DWTX) versus Pulmatrix (NASDAQ:PULM)

Dogwood Therapeutics (NASDAQ:DWTX) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional & Insider Ownership

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 0.2% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Dogwood Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Dogwood Therapeutics and Pulmatrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-2,027.44%	-31.29%
Pulmatrix	N/A	-96.97%	-88.53%

Valuation and Earnings

This table compares Dogwood Therapeutics and Pulmatrix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26 million	($18.90)	-0.09
Pulmatrix	$7.81 million	0.58	-$5.16 million	($1.41)	-0.89

Pulmatrix has higher revenue and earnings than Dogwood Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Dogwood Therapeutics and Pulmatrix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1	0	1	0	2.00
Pulmatrix	1	0	0	0	1.00

Dogwood Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 601.75%. Given Dogwood Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Pulmatrix.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.